Cracking The Code: Understanding Analyst Reviews For Theravance Biopharma
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed reviews on Theravance Biopharma (NASDAQ:TBPH) over the past quarter, with ratings ranging from bullish to indifferent. The average 12-month price target has decreased by 1.67% to $14.75. Key analysts have adjusted their ratings and price targets, reflecting a cautious outlook.
August 06, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Analysts have mixed opinions on Theravance Biopharma, with recent ratings showing a shift from bullish to indifferent. The average 12-month price target has decreased by 1.67% to $14.75, indicating a cautious outlook.
The mixed analyst ratings and slight decrease in the average price target suggest a cautious outlook for Theravance Biopharma. While some analysts maintain a bullish stance, others have lowered their ratings and price targets, indicating uncertainty about the company's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100